CASI Pharmaceuticals, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -3.75 | -100% |
| P/S |
|
2.52 | 33.77 | -92.54% |
|
|
| P/BV |
|
3.53 | 4.83 | -26.83% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
-3.21 | -22.17 | -85.53% |
|
|
| Ev/S |
|
2.64 | 22.57 | -88.29% |
|
|
| Ev/FCF |
|
-4.03 | 68.76 | -105.86% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-82.37 | 4.97 | -1756.59% | -218.55 | -62.31% |
| ROE |
|
-111.48 | 9.61 | -1259.8% |
|
|
| ROA |
|
-35.79 | 0.3443 | -10496.07% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
-79.51 | -25.17 | 215.89% |
|
|
| ROCE |
|
-130.96 | 15.45 | -947.65% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.7032 | -3.68 | -80.87% | -0.5032 | +39.75% |
| Nеt Debt/Ebitda |
|
-0.1489 | -3.44 | -95.67% |
|
|
| Debt/Ratio |
|
0.2607 | 0.1986 | 31.28% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.7285 | 10.32 | -107.06% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.541 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.541 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
726.32 | -57.64 | -1360.1% | ||
| Growth impulse Ebitda in 5 years |
|
-31.4 | -90.94 | -65.47% | ||
| Growth impulse Net Income in 5 years |
|
-47.59 | -97.8 | -51.34% | ||
| Growth impulse FCF in 5 years |
|
-40.46 | -108.72 | -62.79% | ||
| Growth impulse EPS in 5 years |
|
-62.38 | -142.05 | -56.09% |
IP Score
3.43/10
